2019
Clinical implications of circulating tumor DNA tumor mutational burden (ctDNA TMB) in non-small cell lung cancer
Chae YK, Davis AA, Agte S, Pan A, Simon NI, Iams WT, Cruz MR, … Park W, …
The Oncologist 24(6), 820–828
126Citations
2019Year
Related by topic
Publication · NSCLCCost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non–Small Cell Lung CancerPublication · BiomarkerGenomic profiling identifies somatic mutations predicting thromboembolic risk in patients with solid tumorsPublication · BiomarkerMolecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancerPublication · NSCLCOutcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohortProject / Trial · NSCLCSetidegrasib (ASP3082)Publication · NSCLCSetidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
Local graph
Drag to pan · scroll to zoom · drag a node to move · double-click to open